

## Special Issue

# Vaccine Development for Emerging and Zoonotic Diseases

### Message from the Guest Editor

This Special Issue serves as a platform to host original research and comprehensive review articles, all dedicated to the area of emerging and zoonotic animal diseases, with a special focus on vaccine development and the accompanying challenges. The viral disease is not limited to Rift Valley fever virus (RVFV), highly pathogenic avian influenza (HPAI), African swine fever virus (ASFV), and epizootic hemorrhagic disease virus (EHDV). Advancements in vaccine development for zoonotic animal diseases are pivotal, not only for safeguarding animal health but also for enhancing livestock productivity, promoting food security, and mitigating the morbidity and mortality risks associated with potential human and animal diseases. In this Special Issue, we invite authors to submit original research articles and insightful reviews. Research areas to be explored encompass, but are not limited to, the following:

- Novel and emerging pathogen detection in animal;
- Safe and efficacious vaccine approaches to treating Rift Valley fever virus, highly pathogenic avian influenza, African swine fever virus, and epizootic hemorrhagic disease;
- Vaccine-induced immune responses to animal diseases.

---

### Guest Editor

Dr. Velmurugan Balaraman

Department of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA

---

### Deadline for manuscript submissions

closed (1 September 2024)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/188569](https://mdpi.com/si/188569)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).